Covalent EV Capture via Click Chemistry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating tumor-derived extracellular vesicles (EVs) face challenges in selectively purifying them from a background of non-tumor-derived EVs while maintaining the integrity of their biomolecular cargos, leading to poor capture performance and high background noise, which hinders functional studies.
Innovation Solution
The development of EV Click Chips, which utilize covalent chemistry-mediated capture and release, combined with a multimarker antibody cocktail and nanostructured substrates, enables specific and efficient capture of tumor-derived EVs using click chemistry between tetrazine and trans-cyclooctene motifs, followed by disulfide cleavage-driven release, enhancing capture efficiency and reducing background noise.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If immune-affinity capture approaches using antibody-coated beads or antibody-functionalized substrates are used to enrich tumor-derived EVs, then specific capture of tumor-derived EVs is achieved, but capture performance is poor and background noise is high due to limited antigens on EV surfaces
Solution Approach 1:
The patent changes the chemical bonding parameters from reversible immune-affinity binding to irreversible covalent bonding. The capture surface is functionalized with reactive groups (aldehydes, epoxides, or maleimides) that form covalent bonds with nucleophilic groups on EV surface proteins, creating stable and specific capture that overcomes the limitation of weak antigen-antibody interactions.
Solution Approach 2:
The patent replaces the biological immune-affinity recognition system with a chemical covalent bonding system. Instead of relying on antigen-antibody recognition, the invention uses chemically reactive groups on the capture surface to form covalent bonds with EV surface proteins, providing more reliable and specific capture.
2Quantity of substance
If conventional physical enrichment methods such as ultracentrifugation or precipitation are used to isolate EVs, then EV isolation is achieved, but selective purification of tumor-derived EVs from non-tumor-derived EVs is not possible
Solution Approach 1:
The patent applies local quality by creating a capture surface with specific reactive groups localized at the substrate surface. This allows selective chemical interaction with tumor-derived EVs that have been pre-enriched or labeled, while non-tumor EVs pass through without binding, achieving both efficient isolation and selective purification.
Solution Approach 2:
The patent uses reactive chemical groups (aldehydes, epoxides, maleimides) as intermediaries between the capture surface and EV surface proteins. These intermediary groups facilitate specific covalent bonding with tumor-derived EVs, enabling selective purification from the complex mixture of EVs.
3Manufacturing precision
If antibody-based enrichment techniques are used to capture tumor-derived EVs, then tumor-derived EVs can be enriched, but the integrity of enclosed biomolecular cargos may be compromised
Solution Approach 1:
The patent replaces biological antibody-based enrichment with chemical covalent bonding. The reactive groups on the capture surface form direct covalent bonds with EV surface proteins, eliminating the need for antibodies and thereby preserving the integrity of the EV's enclosed biomolecular cargos while maintaining high enrichment specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves high recovery yields and purity of tumor-derived EVs, allowing for intact mRNA analysis and enabling non-invasive early detection of cancers like hepatocellular carcinoma with improved diagnostic performance compared to traditional methods.
Implementation Method 1
utilize covalent chemistry-mediated capture and release, combined with a multimarker antibody cocktail and nanostructured substrates, enables specific and efficient capture of tumor-derived EVs using click chemistry between tetrazine and trans-cyclooctene motifs
Implementation Method 2
followed by disulfide cleavage-driven release
Data Source
AI summary
Methods for selectively capturing an extracellular vesicle (EV) from a sample. including the steps of: functionalizing a capture agent for the EV with a first molecule from a first bioorthogonal functional group such that the capture agent remains attachable to the EV and the first molecule is also able to bond to a second molecule from a second bioorthogonal functional group. the second molecule being complementary to the first molecule: mixing the functionalized capture agent with the sample such that the functionalized capture agent binds to the EV and such that an activated sample is formed: functionalizing a capture surface with the second molecule: and depositing at least a portion of the activated sample on at least a portion of the functionalized capture surface to thereby selectively capture the EV by binding of the second molecule with the first molecule.